Research ArticleExperimental Studies
Open Access

Fibroblast Supernatants Modulate Treatment Responses in Human Papillomavirus Positive and Negative Oropharyngeal Cancer Cell Lines

MADELEINE BIRGERSSON, TERÉZIA CHABANOVÁ, EMILIA WIECHEC, OURANIA N. KOSTOPOULOU and TINA DALIANIS
Anticancer Research November 2025, 45 (11) 4729-4742; DOI: https://doi.org/10.21873/anticanres.17822

Article Figures & Data

Figures

  • Figure 1.
    Figure 1.

    WST-1 viability assay for CU-OP-2 cells treated with targeted therapies and chemotherapeutics ± BJ-hTERT fibroblast supernatant. Cell viability was measured after 24, 48, and 72 h of treatment with: (A) PI3K inhibitor BYL719; (B) FGFR inhibitor JNJ-42756493; (C) CDK4/6 inhibitor PD-0332991; (D) AKT inhibitor AZD-5363; (E) cisplatin; and (F) docetaxel, each with or without BJ-hTERT supernatant. Ratio of viability (drug ± supernatant) to control is shown for (G) 10 μM JNJ-42756493 and (H) 10 μM PD-0332991.

  • Figure 2.
    Figure 2.

    WST-1 viability assay for CU-OP-20 cells treated with targeted therapies and chemotherapeutics ± BJ-hTERT fibroblast supernatant. Cell viability was assessed as in Figure 1 for: (A) BYL719; (B) JNJ-42756493; (C) PD-0332991; (D) AZD-5363; (E) cisplatin; and (F) docetaxel. Viability ratios (± supernatant) are shown for (G) 5 μM JNJ-42756493 and (H) 15 μM docetaxel.

  • Figure 3.
    Figure 3.

    WST-1 viability assay for CU-OP-17 cells treated with targeted therapies and chemotherapeutics ± BJ-hTERT fibroblast supernatant. As in Figures 1–2, viability was measured for: (A) BYL719; (B) JNJ-42756493; (C) PD-0332991; (D) AZD-5363; (E) cisplatin; and (F) docetaxel. Viability ratios (± supernatant) are shown for: (G, H) 5 and 10 μM BYL719; (I, J) 5 and 10 μM JNJ-42756493; and (K) 10 μM PD-0332991.

  • Figure 4.
    Figure 4.

    Confluence analysis of CU-OP-17 cells treated with targeted therapies and chemotherapeutics ± BJ-hTERT fibroblast supernatant. Measured by IncuCyte S3, confluence was recorded for: (A) BYL719; (B) JNJ-42756493; (C) PD-0332991; (D) AZD-5363; (E) cisplatin; and (F) docetaxel. Confluence ratios (± supernatant) are shown for: (G) 1 μM BYL719 and (H) 5 μM PD-0332991.

  • Figure 5.
    Figure 5.

    Confluence analysis of CU-OP-20 cells treated with targeted therapies and chemotherapeutics ± BJ-hTERT fibroblast supernatant. Confluence was monitored as in Figure 4 for: (A) BYL719; (B) JNJ-42756493; (C) PD-0332991; (D) AZD-5363; (E) cisplatin; and (F) docetaxel. Confluence ratios (± supernatant) are shown for: (G) 5 μM PD-0332991 and (H, I) 5 and 10 μM AZD-5363.

  • Figure 6.
    Figure 6.

    Viability and morphological effects of targeted inhibitors ± BJ-hTERT supernatant on CU-OP-20 spheroids. Spheroid viability was measured after 24, 48, and 72 h using RealTime-Glo for: (A) BYL719; (B) JNJ-42756493; (C) PD-0332991; and (D) AZD-5363, each ± BJ-hTERT supernatant. Viability ratios (± supernatant) are shown for: (E, F) 10 and 20 μM JNJ-42756493; (G) 20 μM PD-0332991. (H) Morphological changes in spheroids after 72 h treatment with 10 μM of each drug, ± supernatant, compared to PBS control.

Tables

  • Table I.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Fibroblast Supernatants Modulate Treatment Responses in Human Papillomavirus Positive and Negative Oropharyngeal Cancer Cell Lines
MADELEINE BIRGERSSON, TERÉZIA CHABANOVÁ, EMILIA WIECHEC, OURANIA N. KOSTOPOULOU, TINA DALIANIS
Anticancer Research Nov 2025, 45 (11) 4729-4742; DOI: 10.21873/anticanres.17822
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords